Gestational diabetes & diabetes in pregnancy
Continuous glucose monitoring metrics and pregnancy outcomes in insulin‐treated diabetes: A post‐hoc analysis of the GlucoMOMS trial
Authors' conclusion
In this study, in type 2 diabetes or insulin-treated GDM, the glucose increased area under the curve above limit was associated with increased LGA. In type 1 diabetes, the mean glucose was the major determinant of LGA. Our study found no evidence that other CGM metrics determined adverse pregnancy outcomes.
Study context
- Population
- Pregnant women with insulin-treated DM (type 1, 2 or insulin-treated GDM) randomized to the continuous glucose monitoring (CGM) group of the GlucoMOMS trial; offline intermittent CGM; target range 3.5–7.8 mmol/L (63–140 mg/dL)115 included
- Participants
- 147 women
- Comparison
- Association of CGM metrics with perinatal outcomes by diabetes type
- T1Dn = 50
- T2D/insulin-treated GDMn = 94
Methodological detailspost-hoc analysis, multivariable binary logistic regression
- Post-hoc analysis
- Multivariable binary logistic regression
Primary result
As reported in the abstract
T1D: higher second trimester mean glucose associated with large for gestational age (LGA)
OR 2.6
95% CI 1.1–6.2
T2D/insulin-treated GDM: increased area under the curve above limit associated with LGA
OR 10.0
95% CI 1.4–72.8
Further findings
Neonatal hypoglycaemia, pre-eclampsia, shoulder dystocia, preterm birth and Neonatal Intensive Care Unit (NICU) admission
- None of the CGM metrics were associated with these outcomes for any type of diabetes
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →